Skip to main content

Advertisement

Table 2 Summarized risk ratios (RR) with 95% confidence intervals (95% CIs) for adverse events

From: Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries

Adverse events RR (95% CIs) P value
Maternal adverse events
 Fatigue 1.03 (0.65, 16.25) 0.586
 Cough 1.42 (0.60, 3.39) 0.983
 Diarrhea 3.61 (0.75, 17.41) 0.424
 Fever 1.56 (0.40, 6.17) 0.110
 Nausea 2.06 (0.19, 22.37) 0.523
 Pruritus 0.41 (0.08, 2.08) 0.552
 Palpitation 0.34 (0.01, 8.33) 0.283
 Dyspepsia 3.09 (0.13, 74.99) 0.511
 Rash 0.95 (0.28, 3.19) 0.488
 Insomnia 3.09 (0.13, 74.99) 0.928
 Dizziness 0.52 (0.05, 5.59) 0.488
 Abdominal pain 3.09 (0.13, 74.98) 0.586
 Upper respiratory infection 0.34 (0.04, 3.25) 0.731
 Gestational diabetes 3.41 (0.15, 79.47) 0.351
 Arrhythmia 3.25 (0.28, 46.72) 0.612
Infant adverse events
 Hypospadias 2.78 (0.12, 67.39) 0.529
 Torticollis 1.85 (0.17, 20.08) 0.612
 Umbilical hernia 2.78 (0.12, 67.39) 0.529
 Pneumonia 4.64 (0.23, 95.24) 0.470
 Bronchitis 0.31 (0.01, 7.49) 0.948
 Birth weight < 2500 g 1.10 (0.07, 16.43) 0.185
 Fetal growth retardation 0.79 (0.15, 21.34) 0.546
 Congenital malformation 2.34 (0.25, 64.7) 0.445